Join Us

Would you like to join us?



Let’s work together >


  • Free research grade Molecular reports; These reports will contain clinically actionable molecular alterations.
  • Molecular tumor boards are in place depending on the tumour in order to discuss about best strategy for your patient.
  • Access to all broad profiling data (raw and processed data) from your patients.
  • The patient eligible will be compensated 250 euros (up to 2500 euros for some progression specimen (metastatic patients eligible to IMMUcan).
  • All costs for HBM shipment and analyses are covered
  • Possibility of authorship on publications (e.g. as part of a scientific collaboration).


  • Access to high quality molecular and clinical datasets for biomarker and treatment strategy research (data sharing).
  • Opportunities to propose innovative analysis of IMMUcan left over biological material (sample and data sharing).
  • Material and clinical data are clinical trial grade (longitudinal follow up, quality controlled processes for data and sample collection and processing).